2-ethyl-decanoic acid ethyl ester | 119856-56-3

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 脂肪酰基
• 英文名称: 2-ethyl-decanoic acid ethyl ester
• 英文别名: 2-Aethyl-decansaeure-aethylester；Ethyl 2-ethyldecanoate
• CAS: 119856-56-3
• 化学式: C₁₄H₂₈O₂
• 分子量: 228.375
• InChiKey: ABHZULGDLFSHQE-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  5.5
• 重原子数：
  16
• 可旋转键数：
  11
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.93
• 拓扑面积：
  26.3
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  乙醇 、 2-ethyl-decanoic acid ethyl ester 、 alkaline earth salt of/the/ methylsulfuric acid 生成 2-乙基-1-癸醇
  参考文献：
  名称：

  v. Braun; Teuffert, Chemische Berichte, 1929, vol. 62, p. 240

  摘要：

  DOI：
• 作为产物：
  描述：

  1-氯辛烷 、 alkaline earth salt of/the/ methylsulfuric acid 在 乙醇 作用下， 生成 2-ethyl-decanoic acid ethyl ester
  参考文献：
  名称：

  Pudowik, Zhurnal Obshchei Khimii, 1949, vol. 19, p. 1035,1041

  摘要：

  DOI：

文献信息

• Synthesis and Reactivity of New Aminophenolate Complexes of Nickel
  作者：Siqi Yu、Huan Wang、Jill Sledziewski、Venkata Madhira、Cyrus Takahashi、Michelle Leon、Yulia Dudkina、Yulia Budnikova、David Vicic

  DOI：10.3390/molecules190913603

  日期：——

  New well-defined, paramagnetic nickel complexes have been prepared and characterized by X-ray crystallography. The complexes were found to be active for the cross-coupling of alkyl electrophiles (especially ethyl 2-bromobutyrate) with alkyl Grignard reagents. The ligand architecture in these new complexes could potentially be rendered chiral, opening up future possibilities for performing asymmetric cross-coupling reactions.

  新型明确的顺磁性镍络合物已经被合成并通过X射线晶体学进行表征。发现这些络合物对烷基电亲体（尤其是乙基2-溴丁酸酯）与烷基格里尼耶试剂之间的交叉耦合反应具有活性。这些新络合物中的配体结构可能被设计为手性，从而为未来进行不对称交叉耦合反应开辟了可能性。
• Methods of treating a subject using bioreversible derivatives of hydroxy n-substituted-2-aminotetralins
  申请人：Spriaso LLC

  公开号：US20160016887A1

  公开（公告）日：2016-01-21

  Described are compositions that may be orally administered that comprise a bioreversible derivative of hydroxy N-substituted-2-aminotetralin or an enantiomer or salt or prodrug thereof, and a pharmaceutically acceptable carrier suitable for oral administration in the amount present, wherein the composition is orally bioavailable when administered to a subject. The bioreversible derivative has an intrinsic lipophilicity C log P value of about 7 to about 11.5. A method comprises oral administering such composition to a human subject in need of hydroxy N-substituted-2-aminotetralin therapy.
• COMPOSITIONS COMPRISING BIOREVERSIBLE DERIVATIVES OF HYDROXY N- SUBSTITUTED-2-AMINOTETRALINS, DOSAGE FORMS, AND RELATED METHODS
  申请人：Spriaso LLC

  公开号：US20160015684A1

  公开（公告）日：2016-01-21

  Described are compositions that may be orally administered that comprise a bioreversible derivative of hydroxy N-substituted-2-aminotetralin or an enantiomer or salt or prodrug thereof, and a pharmaceutically acceptable carrier suitable for oral administration in the amount present, wherein the composition is orally bioavailable when administered to a subject. The bioreversible derivative has an intrinsic lipophilicity C log P value of about 7 to about 11.5. A method comprises oral administering such composition to a human subject in need of hydroxy N-substituted-2-aminotetralin therapy.
• COMPOSITIONS COMPRISING BIOREVERSIBLE DERIVATIVES OF HYDROXY N-SUBSTITUTED-2-AMINOTETRALINS, AND RELATED DOSAGE FORMS
  申请人：Spriaso LLC

  公开号：US20180177760A1

  公开（公告）日：2018-06-28

  Described are compositions that may be orally administered that comprise a bioreversible derivative of hydroxy N-substituted-2-aminotetralin or an enantiomer or salt or prodrug thereof, and a pharmaceutically acceptable carrier suitable for oral administration in the amount present, wherein the composition is orally bioavailable when administered to a subject. The bioreversible derivative has an intrinsic lipophilicity C log P value of about 7 to about 11.5. A method comprises oral administering such composition to a human subject in need of hydroxy N-substituted-2-aminotetralin therapy.
• US9956201B2
  申请人：——

  公开号：US9956201B2

  公开（公告）日：2018-05-01